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Retinal micro-vascular and 
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Aim of the study was to evaluate the micro and macro-vascular changes in patients with primary 
hyperparathyroidism (PHPT) compared to controls. 30 postmenopausal PHPT women (15 hypertensive 
and 15 normotensive) and 30 normotensive controls underwent biochemical evaluation of mineral 
metabolism and measurements of arterial stiffness by 24 hour ambulatory blood pressure monitoring. 
Retinal microcirculation was imaged by a Retinal Vessel Analyzer. PHPT patients also underwent bone 
mineral density measurements and kidney ultrasound. PHPT patients had higher mean calcium and 
parathyroid hormone values compared to controls. Evaluating macro-vascular compartment, we found 
higher values of 24 hours-systolic, diastolic blood pressure, aortic pulse wave velocity (aPWV) and aortic 
augmentation index (Aix) in hypertensive PHPT, but not in normotensive PHPT compared to controls. 
The eye examination showed narrowing arterial and venular diameters of retinal vessels in both 
hypertensive and normotensive PHPT compared to controls. In hypertensive PHPT, 24 hours systolic 
blood pressure was associated only with parathyroid hormone (PTH) levels (beta = 0.36, p = 0.04). 
aPWV was associated with retinal diameter (beta = −0.69, p = 0.003), but not with PTH. Retinal artery 
diameter was associated with PTH (beta = −0.6, p = 0.008). In the normotensive PHPT, only PTH was 
associated with retinal artery diameter (beta = −0.60, p = 0.01) and aortic AIx (beta = 0.65, p = 0.02). 
In conclusion, we found macro-vascular impairment in PHPT and that micro-vascular impairment is 
negatively associated with PTH, regardless of hypertension in PHPT.
In primary hyperparathyroidism (PHPT), a combination of structural and functional vascular changes has been 
advocated with conflicting results1. Thus, currently, the presence of atherosclerosis, even with early vascular 
abnormalities or so called vascular impairments, is not included among the criteria needed to submit patients to 
surgery2. Few studies reported that these vascular impairments in PHPT were associated with hypertension3,4, 
while others reported that they were related to high calcium and parathyroid hormone levels which are the bio-
chemical features of PHPT5–7. Other authors did not find any difference between PHPT and controls as regards 
vascular functions8,9.
These results may be due to different calcium levels in the populations studied, or to co-morbidities or also to 
different methods used to measure vascular impairment, namely arterial stiffness.
Currently, regional and local arterial stiffness may be measured directly and noninvasively, at various sites 
along the arterial tree, by assessing pulse wave velocity (PWV) and augmentation index (AIx)10. Aortic PWV has 
been shown to be a powerful predictor of cardiovascular events in the general population11. We chose 24 hour 
ambulatory blood pressure monitoring (ABPM) to determine both PWV and Aix, because this method has never 
been utilized in PHPT populations12. Interestingly, studies suggest that large artery stiffness is also associated 
with micro-vascular changes13. In particular, over the last decade, a large population–based study has shown that 
very small vessels, such as in the retina, are associated with a wide range of subclinical and clinical cardiovascular 
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disease13,14. The retina represents a unique site where the microvasculature can be directly and non-invasively 
visualized, but until now, with a limit of subjective clinical assessment. However, nowadays a modern digital 
imaging systems have revolutionized the assessment of retinal photograph by capturing a larger segment of the 
retina and allowing a more objective documentation. So far, there is no information available regarding retinal 
micro-vascular assessment in PHPT patients.
Our study aimed to provide a preliminary analysis of the micro-vascular retinal vessels using a modern digital 
imaging system and of the macro-vascular compartment using 24 hour ABPM to derive both PWV and Aix in 
PHPT patients with and without arterial hypertension compared to controls.
Results
The characteristics of PHPT patients are reported in Table 1. Seventy - three percent of subjects had densitomet-
ric osteoporosis; morphometric or clinical vertebral fracture were present in 16% of the patients and 13% of the 
patients reported peripheral fractures. Ultrasound revealed renal calculi in 23% of the patients. Serum calcium 
levels higher than 1 mg/dl above the normal range, were present in 13% of the patients. All patients, met the cur-
rent criteria for surgery according to current guidelines, except three patients with mild disease2.
There were no difference between PHPT and controls considering anthropometric parameters, nor between 
hypertensive PHPT patients and normotensive PHPT patients (Table 1).
As expected, mean total and ionized calcium, parathyroid hormone (PTH) and 24 hour urinary calcium were 
higher in both groups of PHPT patients compared to controls (all p < 0.001, Table 1).
No differences were found as regards biochemical evaluation between hypertensive and normotensive PHPT 
patients.
Cardiovascular risk factors were similar between PHPT patients and controls regarding BMI, glucose and 
lipid profile as reported in Table 1. Alcohol consumption was ascertained in 13.3% of the PHPT population and 
in 16.6% of the control subjects (p = ns). Tobacco use was recorded in 20% of the PHPT population and in 26.6% 
of the control subjects (p = ns).
Twelve PHPT patients affected by hypertension were under medication. In particular, 9 patients were under 
alfa-blockers and 3 were under loop-diuretics. The mean time since diagnosis of hypertension was 5 ± 2 years.
We found that hypertensive PHPT patients had higher values of 24 h-systolic, diastolic blood pressure and 
aortic systolic blood pressure (SBP-Ao) as compared to the controls and to the normotensive PHPT group (all 
p < 0.05, Table 2). Seven out of fifteen PHPT patients showed a non physiological decrease in blood pressure 
during night time (non dipper).
Mean baseline best corrected visual acuity was 0.1 ± 0.1 LogMar with a mean refractive error of +1.25 sf.
In the assessment of the macro-vascular compartment, aortic PWV and aortic AIx were significantly higher 
in hypertensive PHPT patients as compared to both the controls and to the normotensive PHPT patients (all 
p < 0.05, Table 2).
The normotensive PHPT patients showed no difference as concerns blood pressure and macrovascular param-
eters compared to the controls.
The eye examination to explore the micro-vascular compartment showed a narrowing arterial and venular 
diameter of the retinal vessels in both hypertensive and normotensive PHPT patients compared to the controls 
(Table 2).
Controls (n = 30)
PHPT Hypertensive 
(n = 15)
PHPT Normotensive 
(n = 15)
Age (years) 61.0 ± 9.8 61.1 ± 4.8 64.8 ± 7.8
Years since menopause (years) 12.4 ± 8.9 15.2 ± 6.2 14.7 ± 7.18
Body mass index (kg/m2) 23.1 ± 2.8 24.9 ± 3.6 23.9 ± 4.2
Creatinine (mg/dl) 0.8 ± 0.1 0.8 ± 0.2 0.7 ± 0.1
Calcium (mg/dL) 9.3 ± 0.4 10.7 ± 0.5** 10.6 ± 0.3§§
Ionized Calcium (mmol/L) 1.2 ± 0.0 1.4 ± 0.1*** 1.4 ± 0.0§§
Phosphorus (mg/dL) 4.0 ± 0.3 2.9 ± 0.3** 2.9 ± 0.4§§
25(OH)D (nmol/L) 34.6 ± 11.4 37.1 ± 11.3 36.4 ± 14.3
Urinary calcium 24 hours 214.0 ± 62.2 264.3 ± 84.7* 274.1 ± 122.0§
PTH (ng/L) 36.4 ± 14.3 100.4 ± 37.4** 80.1 ± 26.3§§
Alkaline phosphatase (U/L) 82.2 ± 23.3 91.5 ± 47.0 83.4 ± 54.7
Glucose (mg/dL) 89.8 ± 6.0 86.7 ± 5.6 88.7 ± 6.5
Total cholesterol (mg/dL) 203.8 ± 31.4 210.6 ± 40.8 190.9 ± 30.0
High Density Lipoprotein (mg/dL) 61.1 ± 13.2 62.2 ± 10.6 57.1 ± 10.3
Low Density Lipoprotein (mg/dL) 121.1 ± 27.5 128.5 ± 25.8 114.9 ± 22.6
Triglycerides (mg/dL) 120.6 ± 38.1 115.13 ± 42.08 124.4 ± 60.7
Table 1. Anthropometric and biochemical parameters in patients with primary hyperparathyroidism (PHPT) 
hypertensive and normotensive and controls. Results are presented as mean ± 1 SD. Controls vs PHPT 
hypertensive *p ≤ 0.05; **p ≤ 0.0001, ***p ≤ 0.00001. Controls vs PHPT normotensive §p ≤ 0.05; §§p ≤ 0.0001.
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We found that 24 h systolic blood pressure and SBP-Ao were associated with PTH levels in the PHPT hyper-
tensive group (beta = 0.36, p = 0.04 and beta = 0.71, p = 0.002 respectively), but not with age, BMI and calcium 
levels. aPWV was associated with retinal arterial diameter (beta = −0.69, p = 0.003), but not with PTH, BMI, 
blood pressure and age. Retinal arterial diameter was negatively associated with PTH (beta = −0.60, p = 0.008, 
Fig. 1A).
In the normotensive PHPT group, we did not find an association between aPWV and retinal vessel diameter, 
nor with PTH neither with blood pressure parameters. The only associations found were a negative association 
between PTH and retinal arterial diameter (beta = −0.60, p = 0.01, Fig. 1B), and a positive association between 
PTH and aortic AIx (beta = 0.65, p = 0.02). Considering all of the PHPT sample and including controls, a nega-
tive association between retinal arterial vessel diameter and PTH was also found (beta = −0.51, p < 0.001, Fig. 2).
Discussion
The strength of this study derives from the demonstration for the first time of a retinal vessel impairment in 
PHPT patients together with macro-vascular abnormalities in hypertensive PHPT patients and a retinal vessel 
narrowing in normotensive PHPT patients, compared to controls. In particular, in PHPT patients with and with-
out hypertension PTH levels are negatively associated with retinal vessel diameter.
The macro-vascular abnormalities shown in our study are in line with previous papers on this topic3,4, while 
the novelty of micro-vascular retinal vessel narrowing in PHPT, regardless of the presence of hypertension, 
deserves attention. Indeed, in the general population, retinal arteriolar narrowing may precede the presentation 
of hypertension by years in initially normotensive individuals, supporting the view that micro-vascular changes 
exert a key role in the evolution from normal to elevated blood pressure15. The atherosclerosis risk in communi-
ties study showed that normotensive participants, who had generalized arteriolar narrowing at baseline, were 60% 
more likely to be diagnosed with hypertension over a 3-year period than individuals who did not have arteriolar 
narrowing16.
The pathophysiological mechanisms that link PTH to vascular compliance markers remain unclear. PTH may 
influence arterial vasculature through the serum levels modification of several molecules such as osteoprote-
gerin or vessel endothelial growth factor17–21. Another plausible explanation is that PTH adversely affects vascular 
smooth muscle cells, which might increase vascular stiffness and promote atherosclerotic changes22,23. Evidence 
from animal and human studies suggests that endothelium is an important regulator of arterial stiffness and 
discussions are still ongoing as to whether endothelial dysfunction contributes to increased arterial stiffness or if 
arterial stiffness causes endothelial alteration, which in turn further increases arterial stiffness.
Considering macro-vascular damage, we observed a higher aPWV in hypertensive PHPT patients, but not a 
higher brachial AIx compared to controls and normotensive PHPT patients.
The AIx is the proportion of central pulse pressure that results from arterial wave reflection and is a commonly 
used measure of arterial stiffness. Although the timing of the arrival of the reflected wave at the proximal aorta 
is largely determined by large artery PW, Aix is not a simple surrogate measure of PWV. It is influenced by vas-
oactive drugs independently of aPWV24 suggesting that it is also determined by the intensity of wave reflection 
which, in turn, is determined by the diameter and elasticity of small arteries and arterioles. However, twin studies 
suggest that AIx is partially heritable and independent of these variable25. It might be possible that in our sample 
Controls (n = 30)
PHPT Hypertensive 
(n = 15)
PHPT Normotensive 
(n = 15)
24 hour ambulatory blood pressure
  24 hour -SBP (mmHg) 116.03 ± 13.71 153.26 ± 6.16** 123.46 ± 7.04°°°
  24 hour –DBP (mmHg) 73.30 ± 14.54 88.26 ± 10.93** 70.2 ± 8.3°°
  MAP (mmHg) 87.37 ± 9.14 109.06 ± 7.14** 88.6 ± 8.79°°
  ABPM-PP (mmHg) 51.18 ± 20.77 71.86 ± 10.02* 51.80 ± 9.06°°
  SBP-AO (mmHg) 118.12 ± 15.48 156.33 ± 8.10** 120.8 ± 10.31°°
  HR (beats/minutes) 73.30 ± 14.49 71.0 ± 6.69 72.8 ± 8.3
Macro-vascular assessment
  Brachial AIx (%) −22.15 ± 22.43 −17.62 ± 8.80 −22.71 ± 11.43
  Aortic AIx (%) 28.74 ± 9.87 42.62 ± 10.88* 30.01 ± 13.67°
  aPWV (m/s) 7.53 ± 2.70 10.81 ± 1.00** 7.97 ± 1.26°°
Micro-vascular assessment
  Retinal artery diameter (μm) 109.47 ± 11.91 99.33 ± 16.53* 101.00 ± 15.37§
  Retinal vein diameter (μm) 133.57 ± 14.40 124.19 ± 19.99* 125.6 ± 14.47§
  AVR (index) 0.86 ± 0.05 0.83 ± 0.06 0.82 ± 0.06§
Table 2. 24 hour parameters of blood pressure, macro-vascular parameters of arterial stiffness and retinal 
micro-vascular parameters in hypertensive and normotensive patients with primary hyperparathyroidism 
(PHPT) and controls. Results are presented as mean ± 1 SD, or percenteges. Legend: SBP = systolic blood 
pressure, DBP = diastolic blood pressure, MAP = mean arterial pressure, PP = pulse pressure, AO = aortic, 
HR = heart rate, Aix = arterial index, aPWV = aortic pulse wave velocity, AVR = retinal artery vein 
ratio. *p ≤ 0.05; **p ≤ 0.0001 Controls vs PHPT hypertensive. §p ≤ 0.05; §§p ≤ 0.0001 Controls vs PHPT 
normotensive. °p ≤ 0.05, °°p ≤ 0.0001, °°°p ≤ 0.0001 PHPT hypertensive vs PHPT normotensive.
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the use of antihypertensive drugs has influenced this parameter; however studying hypertensive patients without 
any medication would have been unethical.
It should be noted that at the moment in Europe and in America there is no specific practical recommendation 
on the use of PWV and AIx and more data are required before these vascular biomarkers can be recommended 
for routine use in the general population12.
However, PWV is a well know factor of increased cardiovascular risk in the general population and it might 
be possible that increased vascular stiffness in subjects with PHPT may account in part for the increased cardio-
vascular risk in this group.
Our study has a few limits. We studied only postmenopausal women of a single geographical area. Thus, men 
and PHPT patients in different countries may show other clinical expressions, as it has been shown for the classi-
cal manifestations of the disease26,27.
Taken together our data point to the role of PTH as a marker of atherosclerosis in PHPT patients not only for 
large vessels but also for small vessels, as it has been suggested also in the general population28.
Moreover our study suggests that the eye examination, which is a non invasive and well know tool for the 
examination of hypertensive patients, may have a possible role also in the clinical assessment of normotensive 
Figure 1. Association between retinal artery vessel diameter and PTH levels in hypertensive PHPT patients (A) 
and normotensive PHPT patients (B).
Figure 2. Association between retinal artery vessel diameter and PTH levels in all the sample studied including 
PHPT patients and controls.
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PHPT, as retinal vessels are a possible target of PTH. We considered in the current study the assessment of a single 
point of the retinal temporal artery and of the retinal temporal vein as representative of the changes in the retinal 
circulation. However more generalized indexes, such as the central retinal arterial equivalent and venular equiv-
alent, might be more suitable indicators of peripheral micro-vascular abnormalities.
Further longitudinal studies are needed to determine the temporal relationship between the development of 
diminished vascular plasticity and possible incident cardiovascular events in PHPT patients. Moreover, since we 
studied patients who met surgical criteria for parathyroid adenoma removal, interest arises, for further research, 
as to whether surgical treatment may influence both macro and micro-vascular abnormalities in PHPT patients.
Methods
Subjects. The population studied included 15 consecutive Caucasian postmenopausal women (age range 
55–75 years old) diagnosed as having PHPT with hypertension and 15 without hypertension at the Metabolic 
Bone Disease Unit of the University of Rome, ‘Sapienza’ (Italy), between January 2017 and February 2018. The 
diagnosis of PHPT was made following the finding of hypercalcemia with an inappropriately high plasma level of 
PTH29. During the same period, in the same center, 30 Caucasian volunteer postmenopausal women in the same 
age range and with the same body mass index (BMI), without hypertension, were enrolled as the control group. 
Exclusion criteria included: BMI > 30 kg/m2, hypo- and hyperthyroidism, previous cardiovascular diseases, pre-
vious medical history of dyslipidemia and/or use of statins, use of beta blocker, angiotensin-converting-enzyme 
inhibitor, estrogen replacement therapy, diabetes mellitus type 1 and 2, creatinine clearance <60 ml/min and  
history of peripheral arterial diseases.
We excluded eyes diseases which could modify retinal vessels, especially a history of glaucoma, retinal vein 
occlusion and retinitis pigmentosa. In addition patients with spherical refractive error ≥±6 diopters, astigma-
tism ≥±3 diopters, optical media opacities that could influence functional and structural retinal testing were 
excluded.
Every patient provided written informed consent. The study was approved by “Policlinico Umberto I” Hospital 
Ethics Committee (protocol number 3454) and by the Institutional Review Board of the G.B. Bietti Foundation. 
The study protocol adhered to the tenets of the Declaration of Helsinki.
After informed consent was obtained, patients and control subjects with 25(OH)D levels lower than 20 ng/mL 
were treated weekly with 50,000 I.U. of cholecalciferol for one month. After completing a validated questionnaire, 
those on a calcium poor diet were supplemented with calcium (1,000 mg) per os daily, which is the recommended 
dose30. After one month of supplementation, both PHPT and controls were reevaluated by blood sample analysis.
Cardiovascular risk factors. BMI was calculated as weight (kilograms) divided by the square of height 
(square meters). Alcohol consumption (more than three alcoholic units per day) and current smoking status were 
assessed in a face-to-face medical interview. Blood pressure (millimetres of mercury) was measured after 5 min-
utes of rest, at the upper left arm with subjects in a lying position and using an oscillometric blood pressure (BP) 
monitor to diagnose hypertension, following the current European Society of Cardiology guidelines31.
Biochemical evaluation. We measured total and ionized calcium, phosphorus, creatinine, glucose, 25(OH) 
vitamin D, parathyroid hormone (PTH), alkaline phosphatase, as described previously32,33. Creatinine clearance 
(CrCl) was calculated using the formula of Cockcroft and Gault. Total cholesterol, high density lipoprotein (HDL) 
and triglycerides (TC) were measured using enzymatic methods (Hitachi 911 analyzer, Roche Diagnostics, Basel, 
Switzerland). LDL was calculated with the Friedewald Formula: LDL = TC − HDL − TG/5.0 (mg/dL).
Skeletal and renal assessment. In PHPT patients, both skeletal and renal assessment were carried out to 
better characterize the disease. Bone mineral density (BMD) of the lumbar spine (L1–L4) in the anterior–poste-
rior projection, of the femur (neck and total hip) and nondominant distal one-third radius was measured in each 
PHPT patient by dual-energy X-ray absorptiometry (Hologic QDR 4500, Hologic Inc, Waltham, MA, USA). The 
precision error of lumbar spine and total hip measurements was 1.3 and 1.7%, respectively and 1.3% at the distal 
1/3 radius34. Fractured lumbar vertebrae were excluded from BMD measurement. Each patient subject under-
went morphometric vertebral assessment (VFA) with the DXA scan35. Abdominal ultrasound was performed by 
a skilled radiologist to detect renal calculi, with an ultrasound scanner (Esaote MyLab 70 x Vision; Genoa, Italy), 
as previously described36.
Non-invasive vascular studies. All participants underwent 24 hour ABPM. They were instructed to keep 
their non-dominant arm still at the side during measurements. Measurements were carried out by using the 
24 hour TensioMed Arteriograph system (TensioMed Ldt., Budapest, Hungary). The automatic monitoring sys-
tem was set up to obtain measurements every 15 minutes while subjects were awake and every 30 minutes while 
the subjects were sleeping. Details of this device have been previously described12. This technique is based on the 
fact that the contraction of the myocardium generates pulse waves in the aorta. The pulse wave goes to the arm 
(first wave), where the cuff is located, then to the aorta. Part of the wave is reflected at the bifurcation of the aorta, 
goes back, adds to the first and is sensed by the cuff. The first wave is reflected at the bifurcation of the aortic wall; 
a second, reflected wave therefore appears as a late systolic peak.
The morphology of this second wave depends on the stiffness of the large artery, the reflection time at 
35 mmHg suprasystolic pressure of the brachial artery and the peripheral resistance-dependent amplitude. 
The cuff collects a pulse wave that contains both the first and reflected waves. The software calculates aortic 
PWV (aPWV) and AIx from this combined wave. The speed with which the pulse wave travels along the jugular 
fossa-symphysis distance is aPWV. The jugular fossa–symphysis distance is anatomically identical to the distance 
between the aortic trunk and the bifurcation. Because PWV indicates the pulse wave speed in the arterial tree: 
if the artery is stiff, the speed is increased. The AIx is defined as the percentage ratio of the pressure increment 
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caused by the reflected wave to the direct wave. Normally, the reflected component in peripheral waves is always 
smaller than the direct component and AIx is negative.
Retinal vessel assessment. In order to exclude other diseases that may modify retinal vessel diameter, each 
patient received a comprehensive ophthalmological assessment which involved a visual acuity and a slit-lamp 
examination, a Goldmann applanation tonometry and an ocular fundus evaluation.
All patients and controls were imaged by a Retinal Vessel Analyzer (RVA) by positioning the subject in front 
of a non-midriatic camera (TopconTRC-NV2000) to obtain a retinographic image (45°). The images were then 
processed by IMEDOS software measuring the caliber of vessels emerging from the optic disc, as previously 
described37. In particular, the RVA produces continuous and automated analysis of the vessels combined with 
correction for small eye movements. Using an adaptive algorithm to calculate the size of the vessels (Vessel Map 
2-Z), this system combines high reproducibility with high temporal and of spatial resolution.
Measurements of the right eye were taken: in particular superior temporal retinal artery diameter (RAD), 
superior temporal retinal vein diameter (RVD) and artery-vein ratio (AVR) were taken between 1 and 2 disc 
diameters from the margin of the optic disc major (Fig. 3). Generally we considered the more temporal vein as 
“superior temporal vein” and the other vessel was recognized as a medial retinal vein or tributary vessel of the 
superior temporal vein38.
In view of the high reproducibility of the procedure, only one acquisition session was scheduled for each 
subject. One single measurement was performed by positioning the caliber at the outer margin of the first circle 
delimitating the optic disc39, due to the results of a previous study demonstrating the high correlation in vascular 
morphology between the left and the right eye40.
Statistical analysis. Statistical analysis was performed using SPSS for Windows version 13 (SPSS Inc., Chi, 
IL, USA). Categorical variables are described with numbers and percentages. Continuous variables are expressed 
as mean value ± SD. Differences between groups were assessed with chi-squared test for categorical variables. 
We checked all variables in the three groups for normality. For comparison of continuous variables that failed to 
pass normality test, we used the Mann – Whitney test. For comparison of continuous variables was made using 
unpaired t-test. Pearson correlation coefficient (beta) was calculated for the measurement of micro-vascular and 
macro-vascular parameters with biochemical and anthropometric values. A p value < 0.05 was considered sta-
tistically significant. As there are no data on retinal vessels in PHPT, it was not possible to calculate a sample size; 
thus, we decided to include at least 15 hypertensive patients, considering the previous study where 15 patients 
affected by PHPT and hypertension had a significantly different AIx compared to controls6.
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